GleamWall
中文EN

ACON Aclarion, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1635077 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY46.0%
TTM net income YoY-37.9%
TTM EPS YoY99.7%
Revenue 3-yr CAGR5.4%
Net income 3-yr CAGR—

Margins

Gross margin29.1%
Operating margin-10,789.2%
Net margin-10,260.0%
FCF margin—
EBITDA margin-10,662.3%

Returns

ROE-74.1%
ROA-69.7%
ROIC (approx.)-958.9%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets6.5%
Debt / equity0.00x
Current ratio14.17x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$33,733$25,208$21,140$18,479$18,942$19,319$18,991$10,232
Cost of revenue$18,937$16,911$17,390$16,688$14,556$14,179$23,479$20,556
Gross profit$14,796$8,297$3,750$1,791$4,386$5,140-$4,488-$10,324
R&D expense$371,511$297,070$315,417$263,130$302,037$270,434$198,190$251,826
SG&A expense$1.64M$1.73M$1.77M$1.11M$900,904$1.13M$986,663$1.21M
Operating income-$2.75M-$2.90M-$2.99M-$1.99M-$1.83M-$1.74M-$1.49M-$1.81M
Pretax income-$2.62M-$2.75M-$2.85M-$1.89M-$1.71M-$1.60M-$2.04M-$1.99M
Income tax$0$0$0$0$0$0$0$0
Net income-$2.62M-$2.75M-$2.85M-$1.89M-$1.71M-$1.60M-$2.04M-$1.99M
EBITDA-$2.75M-$2.90M-$2.93M-$1.93M-$1.83M-$1.74M-$1.44M-$1.75M
EPS (basic)-0.94-1.12-1.34—-2.93-2.75-9.32—
EPS (diluted)-0.94-1.12-1.34—-2.93-2.75-9.32—
Weighted avg. shares (diluted)2.78M2.46M2.13M—582,371582,371219,366—
Banking
Deposits——————$1.39M$463,661
Balance sheet
Cash & equivalents$14.19M$16.29M$19.00M$12.02M$11.37M$12.85M$14.76M$463,661
Receivables$33,243$28,172$40,583$29,680$32,018$20,920$19,172$18,326
Current assets$14.58M$16.79M$19.38M$12.40M$11.90M$13.44M$15.16M$824,279
PP&E, net$21,786$23,233$22,872$24,169$13,164$6,461$5,093$5,499
Intangibles$1.23M$1.22M$1.24M$1.25M$1.28M$1.31M$1.32M$1.29M
Total assets$15.83M$18.04M$20.64M$13.67M$13.20M$14.75M$16.48M$2.12M
Current liabilities$1.03M$1.04M$986,208$837,287$699,747$564,422$699,032$1.15M
Total liabilities$1.03M$1.04M$986,208$837,287$699,747$564,422$699,032$1.15M
Shareholders' equity$14.81M$17.00M$19.65M$12.84M$12.50M$14.19M$15.78M$970,057
Shares outstanding2.88M2.46M2.44M854,371582,371582,371582,3381,370
Cash flow statement
Operating cash flow-$2.02M-$2.66M-$2.64M-$1.63M-$1.16M-$1.87M-$2.51M-$922,861
Capital expenditure$0——$13,726$7,321——$5,115
Free cash flow-$2.02M——-$1.64M-$1.17M——-$927,976
Investing cash flow-$72,830-$43,179-$49,345-$41,461-$40,151-$44,002-$78,288-$60,717
Financing cash flow-$6,325-$19,284$9.68M$2.34M-$283,798-$1$16.89M$125,142
Depreciation & amortization$1,447$1,447$60,909$61,313$618$466$55,167$52,246
Stock-based compensation$424,821$102,117$4,694$4,365$16,746$28,360$55,897$56,618

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.